Trial
NCT00651378
Switching to Rosuvastatin Versus Adding Ezetimibe to Atorvastatin Versus Doubling the Dose of Atorvastatin in Patients With Hypercholesterolemia and Risk Factors (P03708)
Phase IVTERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Organon and Co
Collaborators
Merck Sharp & Dohme LLC
Condition
Hypercholesterolemia
Intervention
Rosuvastatin
Why stopped
Slow enrollment \[HIGH SCREEN FAILURE RATE\]
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-08-15